Trial Profile
Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results investigating efficacy and safety presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.